about us
about us

Company Profile

Company Profile

Hengsai BiotechnologyFounded in 2018, is dedicated toDendritic Cell Vaccine (DC Vaccine)The company is a scientific and technological innovative enterprise and a national high-tech enterprise in R&D and industrialization. The company has successfully constructed the Eco-DCVax platform, aiming to break the technical barriers to industrialization and develop globalFirst-in-Classa high quality DC vaccine product that is safe, efficient and easy to administer. Developed products -therapeutic dendritic cell vaccineIt provides new ways and strategies for the treatment of relapsed and refractory tumors, chronic viral infections, autoimmune diseases, and other diseases that are in urgent need of effective clinical treatments.

Hengsai Bio's R&D center and pilot plant in Shanghai Lingang Blue Bay officially came into operation in 2021, and a large-scale R&D/production base is under construction. The company has now established stable cooperative relationships with a number of domestic and foreign research institutions and tertiary hospitals, and is in the process of dual-reporting between China and the U.S. to carry out clinical research and technical cooperation in order to comprehensively verify the clinical safety and effectiveness of the DC vaccine.